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11h-Hydroxysteroid dehydrogenases type 1 and 2 (11h-HSD1 and 11h-HSD2) are microsomal enzymes responsible for the
interconversion of cortisol into the inactive form cortisone and vice versa. 11h-HSD1 is mainly present in the liver, and has predominantly
reductase activity although its function has not yet been elucidated. 11h-HSD2, present in mineralocorticoid target tissues such as the kidney,
converts cortisol into cortisone. Reduced activity due to inhibition or mutations of 11h-HSD2 leads to hypertension and hypokalemia
resulting in the Apparent Mineralocorticoid Excess Syndrome (AMES). Like humans, cats are highly susceptible for hypertension. As large
species differences exist with respect to the kinetic parameters (Km and Vmax) and amino acid sequences of both enzymes, we determined
these characteristics in the cat. Both enzyme types were found in the kidneys. 11h-HSD1 in the feline kidney showed bidirectional activity
with predominantly dehydrogenase activity (dehydrogenase: Km 1959F 797 nM, Vmax 766F 88 pmol/mg*min; reductase: Km 778F 136
nM, Vmax 112F 4 pmol/mg*min). 11h-HSD2 represents a unidirectional dehydrogenase with a higher substrate affinity (Km 184F 24 nM,
Vmax 74F 3 pmol/mg*min). In the liver, only 11h-HSD1 is detected exerting reductase activity (Km 10462 nM, Vmax 840 pmol/mg*min).
Sequence analysis of conserved parts of 11h-HSD1 and 11h-HSD2 revealed the highest homology of the feline enzymes with the
correspondent enzymes found in man. This suggests that the cat may serve as a suitable model species for studies directed to the pathogenesis
and treatment of human diseases like AMES and hypertension.
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1. Introduction dependency, but also in molecular weight and amino acidThe microsomal 11h-hydroxysteroid dehydrogenases
(11h-HSDs) convert bioactive glucocorticosteroids (corti-
sol and corticosterone) into their inactive keto-metabolites
(cortisone and dehydrocorticosterone) and vice versa.
Therefore, 11h-HSDs play an important role in the
regulation of local levels of bioactive glucocorticoids,
resulting in different physiological effects. Two distinct
types of 11h-HSD have been characterised extensively.
They not only differ in kinetic characteristics, such as
prevailing reaction direction, Michaelis–Menten constant
(Km), maximum enzyme velocity (Vmax) and co-substrate0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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The first described type (11h-HSD1) is mainly present in
the liver but also found in many other tissues [2,3] and
although this enzyme is bidirectional, reductase activity
dominates. This enzyme requires NADP(H) as cofactor
[4–9]. Another feature is the relatively low substrate affinity
(Michaelis–Menten constant in the micromolar range) in
comparison to 11h-HSD2. The molecular weight of 11h-
HSD1 is approximately 34 kDa [2]. The cofactor binding
pocket and the active site are highly conserved sites of the
enzyme [10]. The exact function of 11h-HSD1 is not yet
fully elucidated; besides the conversion of glucocorticoste-
roids, this enzyme might also play a role in detoxification
processes [11], inflammation [12], insulin sensitivity [13]
and obesity [14].
In contrast to 11h-HSD1, 11h-HSD2 is a unidirectional
dehydrogenase as it converts the biologically active glu-
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cortisone. For this conversion, NAD is required [15]. The
Km is in the nanomolar range, indicating a higher substrate
affinity than 11h-HSD1. The molecular weight is approx-
imately 44 kDa [16,17] although also a molecular weight
is described of 41 kDa [18,19] and 48 kDa [17]. The
enzyme consists of five conserved regions (A–E), with the
cofactor binding site (A) and the active site (D) as the
most important [20]. Sequence analysis of human 11h-
HSD2 showed only 18% homology with human 11h-
HSD1. 11h-HSD2 is mainly present in mineralocorticoid
target tissues such as the kidney, salivary gland and distal
colon, but has also been found in the placenta. In the
kidney, it co-localises with the mineralocorticoid receptor,
which has equal affinity for aldosterone and the bioactive
glucocorticoid cortisol. In this way, 11h-HSD2 preserves
aldosterone specificity on the nonselective mineralocorti-
coid receptor by inactivating glucocorticoids locally [21].
Partial or complete inhibition of 11h-HSD2 activity in
mineralocorticoid target tissues results in hypertension and
hypokalemia due to overstimulation of the mineralocorti-
coid receptor by cortisol which circulates in much higher
levels than aldosterone [22]. In the placenta, 11h-HSD2
protects the foetus against high circulating levels of
maternal glucocorticoids [23]. Decreased activity in the
placenta is associated with low birth weight and develop-
ment of hypertension later in life [24]. In humans, several
point mutations in the gene encoding for 11h-HSD2 are
described. Each of these is responsible for mild to severe
abnormalities in cortisol metabolism and hypertension
[25]. Moreover, experimental gene deletion of 11h-
HSD2 in mice resulted in severe hypertension in this
species [26].
It is well known that remarkable species differences exist
with respect to tissue distribution of the 11h-HSD types: in
human kidney predominantly 11h-HSD2 is present
[19,20,27], while in the kidney of the rat [28–31], guinea
pig [5,6] and mouse [32,33] 11h-HSD1 and 11h-HSD2
have been demonstrated by both activity studies and RT-
PCR. 11h-HSD1 is present in liver tissue of rat [7,28,29,34],
mouse [32] [35], man [27,36] and guinea pig [5,6], while in
koala liver this enzyme is absent [37].
Another feature that differs between the species is
the predominant activity of 11h-HSD1. In guinea pig
[6], mouse [35], sheep and human liver microsomes
[27], 11h-HSD1 has bidirectional activity, but reductase
activity prevails. In rats, large interstrain differences
have been found. In Wistar–Kyoto rats bidirectional
activity was established [28] whereas in Sprague–Daw-
ley rats [7] only dehydrogenase activity has been
detected.
The enzyme kinetics of 11h-HSD2 show more constan-
cy in the different species investigated. The main activity of
this NAD-dependent enzyme is dehydrogenation, and the
substrate affinity is higher than the substrate affinity of
11h-HSD1.Since 11h-HSD2 is known as the NAD-dependent form
of 11h-HSD, controversial findings have been reported in
mouse [35], rat [28] and guinea pig [5,6], as besides the
NADP(H)-dependent form (11h-HSD1), also a bidirectional
NAD(H)-dependent enzyme has been found in the liver. As
even Northern blot analysis did not confirm the presence of
11h-HSD2 in the liver of these species [5,33,38], it was
suggested that other forms of 11h-HSD might exist.
In contrast to other animal species, cats are susceptible
for hypertension as known from clinical studies [39].
However, in hypertension research, most often rats [40,41]
and mice [42] are used. These animals have corticosterone
as physiological glucocorticosteroid, while humans and cats
have cortisol. Although both glucocorticosteroids are con-
verted by 11h-HSD, the affinity of the glucocorticosteroids
for the enzyme differs considerably [35,43].
As impaired cortisol metabolism, due to inhibition or
mutation of 11h-HSD2, plays a role in the pathogenesis of
hypertension in man and probably explains the high sus-
ceptibility of cats for hypertension, we characterised both
11h-HSDs by assessing enzyme kinetic parameters in feline
kidney- and liver microsome fractions. For confirmation of
distinct 11h-HSD1 and 11h-HSD2 enzymes, cDNA derived
from cat liver and kidney was sequenced.2. Materials and methods
[1,2,6,7-3H] cortisol (60.0 Ci/mmol) was purchased
from Amersham Pharmacia Biotech (Arlington Height,
IL, USA) and [1,2-3H] cortisone (50 Ci/mmol) was
obtained from American Radiolabeled Chemicals (St.
Louis, MO, USA). Nonradioactive steroids and the cofac-
tors (NAD, NADH, NADP, NADPH) were obtained form
Sigma Chemical Co. (St. Louis, MO, USA). TLC-plates
(silica gel 60 F254, 20 20 cm) and ethyl acetate were
from Merck (Darmstadt, Germany). The scintillation fluid
was Ultima Gold from Packard Bioscience (USA). All
other chemicals were of analytical grade. Fresh kidney and
liver tissue were obtained from three clinical healthy male
cats (Felis cattus). No abnormalities were found neither
during serum analysis (urea, creatinine, bile acids, ALAT,
calcium, total protein, albumin) nor in hematocrit values
and leukocyte counts.
For sequence analyses, RNA of both tissues was
isolated using Qiagen RNeasy Mini Kit. The Dnase
was purchased from Qiagen Rnase-free Dnase kit. The
poly(dT) primers were incubated in the Reverse Tran-
scription System from Promega (Leiden, the Netherlands).
Platinum Taq polymerase was purchased from Invitrogen
(The Netherlands). To purify the PCR product, QIAquick
Gel Extraction Kit (Qiagen) was used. The sequencing
was performed with ABI PRISM Big Dye Terminator
Cycle Sequencing Kit. The fragments were analysed with
an automatic sequencer ABI PRISM model 3100 (Ap-
plied Biosystems) (The Netherlands).
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After removal of the renal capsule and the pelvis, the
kidneys were put in liquid nitrogen and stored at  70
jC until further preparation. From the livers, representa-
tive cross sections were taken and stored in the same
way. Microsomes were prepared by a standard procedure
as described previously [44]. In short, all tissues were
homogenised with a Potter S (B. Braun Biotech Interna-
tional, Melsungen, Germany) in 2 volumes of ice-cold
potassium chloride (1.15%) containing 0.1 mM EDTA.
All subsequent steps were performed at 0–4 jC. The
tissue homogenate was centrifuged at 10,000 g for 25
min. The supernatant was decanted and centrifuged at
100,000 g for 75 min. The pellet was suspended in
KCl/EDTA solution, homogenised with a Utra-turrax T25
(Janke and Kunkel, Germany) and again centrifuged at
100,000 g for 75 min. Finally the pellet was homoge-
nised again with the Ultra-turrax and resuspended in
phosphate buffer (pH 7.4, 1.5 mM MgCl26H20, 0.1
mM EDTA) containing 20% glycerol, frozen in liquid
nitrogen and stored at  70 jC until use. Protein quan-
tification was performed with the method described by
Lowry [45].
2.2. Assay of 11b-dehydrogenase activity
Liver and kidney microsomes were pooled from three
male cats. Incubations were carried out in 2-ml Eppendorf
micro-test tubes in a 37 jC water bath for 15 min. The
total incubation volume was 250 Al, containing 4 mM
cofactor (NAD+, NADP+), [3H]-cortisol (0.5 ACi per
incubation) and unlabeled cortisol (30 nM–1500 nM in
the NAD-dependent experiments, 420–25,000 nM in the
NADP-dependent experiments) and 0.05M phosphate
buffer (pH 7.4). The reaction was started by adding the
microsome fraction. After 15 min, the reaction was
arrested by addition of 1.5 ml ethyl acetate and putting
the samples on ice. The ethyl acetate fraction was
transferred to a tube containing 50 Al (1.1 mM) unlabeled
cortisol and 50 Al (1.1 mM) cortisone to mark the
position of [3H]-labelled steroids on TLC plates later
on. After evaporation of the ethyl acetate under nitrogen,
the residue was dissolved in chloroform/methanol (50:50
v/v) and separated by TLC using chloroform/methanol
(9:1, v/v) as a mobile phase. The spots containing cortisol
and cortisone were detected by UV illumination, cut out
and transferred into separate vials containing 12 ml
scintillation liquid. To elute the labelled steroids from
the TLC matrix, the vials were shaken for 2 h. To avoid
loss of accuracy by air bubbles, the radioactivity was
measured 48 h later using a 4700 PW liquid scintillation
counter. In initial studies, the protein concentration in
each reaction was adjusted to ensure the linearity of
product formation over the incubation time. To keep the
conversion rates between 5% and 40%, the amount ofprotein per incubation was optimised for every cofactor-
dependent experiment (0.020 and 0.016 mg in the experi-
ments in the kidney with NAD and NADP, respectively).
All values were corrected with blank incubations, in
which all assay components were present, except the
microsomes.
2.3. Assay of 11-reductase activity
11-Reductase activity was determined similar to the
11h-dehydrogenase assay except that 3H-cortisone (0.5
ACi per incubation) and cortisone (420–25000 nM) were
used as substrates and NADH/NADPH as cofactors.
Optimised conditions for the kidney experiments were
0.041 mg protein and an incubation time of 15 min, and
in the liver 0.058 mg protein and 30 min incubation
time.
2.4. Analysis of enzyme kinetic data
The enzyme velocity was determined by calculating of
the conversion rate of cortisol into cortisone or the
backward conversion. Data are expressed in picomoles
per milligram of protein per minute (pmol/mg min). All
data reported represent means of three to five indepen-
dent incubations. Kinetic analyses were performed with
EZ-FIT [46]. Significance of the effects of cofactors on
Km and Vmax was evaluated using a two-sided unpaired
Student’s t test.
2.5. RT-PCR
Total cellular RNA was isolated from frozen feline
tissues by using Qiagen RNeasy Mini Kit according to
the manufacturer’s instructions. Total RNA (1 Ag) was
incubated with poly(dT) primers using the Reverse Tran-
scription System at 42 jC for 15 min, followed by
inactivation at 95 jC for 5 min. Putative feline 11h-HSD1
primers (set 11h-HSD1: sense, 5V-TTCAGACCAGA-
GATGCTCC-3V; antisense, 5V-CCTTTGATGATCTC-
CAGGGC-3V), were designed from the conserved regions
of human (AY044083), sheep (AF414124), and rat 11h-
HSD1 (NM_0127080) cDNAs. Putative feline 11h-HSD2
primers (set 11h-HSD2: sense, 5V-CCGGCTGTGACTCT-
GGTTTTG-3V; antisense, 5V-CCATGCAAGTGCTCGATG-
TAGTC-3V) were designed from the conserved regions of
human (U27317), sheep (AF414125), and rat 11h-HSD2
(NM_017081) cDNAs. The PCR reaction mixture contained
2.5 units of Platinum Taq polymerase, 20 pmol each of
sense and anti-sense primer, 200 AM dNTPs, 50 mM KCl,
15 mM Tris–HCl, and 0.5 mM MgCl2. cDNA was ampli-
fied for 40 cycles under the following conditions: denatur-
ation at 94 jC (1 min), annealing at 50 jC for 11h-HSD1
and at 55 jC for 11h-HSD2 (1 min), and extension at 72 jC
(1 min). PCR products were separated by electrophoresis on
an ethidium bromide-stained agarose gel (1.5%) using
Table 1
Kinetic parameters of feline kidney 11h-HSD
Kidney Dehydrogenase activity Reductase activity
Conversion Cortisol!Cortisone Cortisone!Cortisol
Cofactor NAD NADP NADH NADPH
Km (nM) 184F 24 1959F 797 n.d. 778F 136
Vmax (pmol/mg min) 74F 3 766F 88 n.d. 112F 4
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ultraviolet transilluminator. The PCR products (11h-HSD1:
664 bp and 11h-HSD2: 652 bp) were cut out of the agarose-
gel and purified using the QIAquick Gel Extraction Kit.
Sequences of both strands were obtained using
Standard sequencing procedures (ABI PRISM 3100
Genetic Analyser, Applied Biosystems, Foster City,
CA, USA). Enzyme kinetic parameters of 11h-HSD in the feline kidney. Dehydrogena-
tion of cortisol and reduction of cortisone with NAD(H)/NADP(H) are
determined. Values are meansF S.E. of three experiments. n.d. means not
detectable.3. Results
3.1. Kinetic parameters of 11b-HSD in feline kidney
In feline kidney a high affinity unidirectional NAD-
dependent dehydrogenase was found. These character-
istics are typical for 11h-HSD2. Moreover, a bidirection-
al NADP(H)-dependent enzyme was found, with equal
low affinity for cortisol and cortisone, but with a higher
Vmax for dehydrogenation of cortisol into cortisone
(766F 88 pmol/mg min) than for the reduction of cortisone
into cortisol (112F 4 pmol/mg*min). The conversion of
cortisol into cortisone and the reverse reaction follow
Michaelis–Menten kinetics as the Lineweaver–Burk plot
shows linearity (for example see Fig. 1). The enzymeFig. 1. Lineweaver–Burk plot of NADP-dependent dehydrogenase and
NADPH-dependent reductase in feline kidney microsomes. The micro-
somes were incubated with 3H-cortisol and unlabelled cortisol in the
presence of excess of NADP at 37 jC for 15 min for the NADP
dehydrogenase activity. For the reductase activity, the microsomes were
incubated with 3H-cortisone and unlabelled cortisone in the presence of
excess of NADPH at 37 jC for 30 min. The Km for the dehydrogenase
reaction is 1959F 797 nM and the apparent Vmax is 766F 88 pmol/
mg*min (mean of 3 experimentsF S.E.). The Km for the reductase reaction
is 778F 136 nM and the apparent Vmax is 112F 4 pmol/mg*min (mean of
3 experimentsF S.E.).kinetics of the conversion of cortisol and cortisone are
listed in Table 1.
3.2. Kinetic parameters of 11b-HSD in feline liver
Liver microsomes of cat showed unidirectional NADPH-
dependent reductase activity. No dehydrogenation could be
detected. The mean Km of this reductase reaction was 10462
nM and the mean Vmax was 182 pmol/mg min. The
NADPH-regenerating system did not elevate the reaction
velocity (data not shown). Enzyme kinetics of 11h-HSD in
the liver are summarised in Table 2.
3.3. RT-PCR of 11b-HSD1
The primers for 11h-HSD1 were based on conserved
regions of 11h-HSD1 in three species (human, sheep, rat)
with the primers as described in Materials and methods. In
feline liver and kidney a 581-bp fragment was detected
(see Fig. 2).
The sequence of the fragment found with 11h-HSD1
primers in the liver and the kidney was:AAGTGATTGT-
CACAGGGGCCAGCAAGGGGATTGGAGAACA-
GATGGCCTATCATCTGGCAAAGATGGGAGCC-
CATGTGGTGGTGACAGCAAGGTCTAAAGAAAATC-
TAAAGAAGATAGTATCCCATTGCATGGAGCTTG-
GAGCAGCCTCAGCACACTACATTGCTGGCACCATG-
GAGAATATGACCTTCGCAGAGCAATTTGTTGC-
CAAAGCTGGAAAGCTCATGGGGGGACTAGA-
CATGCTTATTCTCAACCACATCACCAACACTTCTAT-Table 2
Kinetic parameters of feline liver 11h-HSD
Liver Dehydrogenase activity Reductase activity
Conversion Cortisol!Cortisone Cortisone!Cortisol
Cofactor NAD NADP NADH NADPH
Km (nM) n.d. n.d. n.d. 10,462F 840
Vmax (pmol/mg min) n.d. n.d. n.d. 182F 6
Enzyme kinetic parameters of 11h-HSD in the feline liver. Dehydrogena-
tion of cortisol and reduction of cortisone with NAD(H)/NADP(H) are
determined. Values are meansF S.E. of three experiments. n.d. means not
detectable.
Fig. 2. Fragments of 11h-HSD1 and 11h-HSD2 in the liver and kidney of the cat. The primers for 11h-HSD1 and 11h-HSD2 were based on conserved regions
of the enzymes in three species (human, sheep, rat). In the kidney both 11h-HSD1 and 11h-HSD2 are found, while in the liver only 11h-HSD1 could be
detected.
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GAAGCATGGAAGTCAACTTCCTCAGTTATGTGGTC-
CTGAGTGCTACTGCCTTGCCTATGCTGAAGCAGAG-
C A AT G G A A G C AT T G T T G T C G T G T C C T C -
G AAGGC TGGGAAAATGGC TAG T CCAC T-
TATTGCGCCCTATTCTGCAAGCAAGTTTGCCCTG-
GATGGGTTTTTCTCCTCCATCAGGATGGAACATT-
CAGTGGCCAAGATTAATGTATCGATCACTCTCTG-
TATCCTCGGCCTCATAAACACAGACACAGCCAT-
GAATGCCATTTCTGGA.
The amino acid sequence of this RT-PCR fragment is
homologous to 11h-HSD1 in various species. Highest ho-
mology (83,4%) was found with 11h-HSD1 from humans
(Homo sapiens, see Table 3). This confirms the presence of
11h-HSD1 in the feline liver and kidney. Details on the
homology of feline 11h-HSD1with other species are listed in
Fig. 3.
The cofactor binding pocket of 11h-HSD1 in the cat has
a unique sequence, which differs in two amino acids from
the other species (amino acids 48 and 49). The active site of
11h-HSD1 (amino acids 183–200) shows highly conservedTable 3
Homology between feline 11h-HSD1 and other species, based on a 192-
amino-acid fragmentparts. Amino acid 199 varies between the species, including
the cat. Amino acid 197 is isoleucine in man, mouse, rat and
cat, whereas in sheep, cow and guinea pig, leucine is at
position 197.
3.4. RT-PCR of 11b-HSD2
The primers for 11h-HSD2 were based on conserved
regions of 11h-HSD2 in three species (human, sheep, rat)
and tested in feline kidney and liver. Only in the kidney, a
corresponding fragment was found (see Fig. 2). The sequence
of this 666-bp fragment was: TTTTGCGCCCCTCCGCGC-
CTTTCGGTGGCCACTCGCGCGGTGCTCAT-
CACCGGCTGTGACTCTGGTTTTGGCAAGGA-
GACGGCAAAGAAGCTAGACGCTATGGGCTT-
CACGGTGCTGGCCACCGTGTTGGAGTTGGATGGC-
CCTGGTGCCCTAGAGCTGCGTGCCTGCTGTTCCCC-
TCGCCTAAGGCTGCTGCAGCTGGACCTGACCAAG-
CCAGCAGACATCAGCCGAGCACTGGAGTTCACAA-
AGGCCCACACCACCAGCACAGGCTTGTGG-
GGCCTGGTCAACAATGCAGGCCACAACAATG-
TAGTGGCCGATGTGGAGCTGTCTCCAGTGGCCAC-
ATTCCGCAGCTGCATGGAGGTGAATTTCTTCGGT-
GCGCTTGAACTAACCAAGGGCCTGTTGC -
CACTGCTGCGGCGTTCTAGGGGTCGCATCGT-
GACTGTGGGCAGCCCAGCAGGAGACATGCCA-
TACCCATGCTTGGCGGCCTATGGGTCCTC -
CAAAGCGGCCATGGCACTGCTCATGGACACATT-
CAGCTGTGAACTTCTGCCCTGGGGGGTCAAGGT-
CAGCATCATCCAGCCTGGCTGCTTCAAGACA-
GAGTCTGTGCAGAATGTGGGCCAGTGGGAG-
CAGCGTAAACAGCTGCTGCTGGCCAGCCTGCCCC-
GAGAGCTGCTCCAG.
The amino acid sequence of this RT-PCR fragment is
homologous to 11h-HSD2 in various species. The highest
homology (89,6%) was found with humans (Table 4).
Fig. 3. Amino acid sequence of a part of feline 11h-HSD1 in comparison with other species. The underlined amino acids indicate the cofactor binding pocket
(34–63), highly conserved consensus sites for N-glycosylation (162 and 217), and the active site of the enzyme (183–200).
Table 4
Homology between feline 11h-HSD2 and other species, based on a 220-
amino-acid fragment
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species are listed in Fig. 4.4. Discussion
In the kidney of the cat, the presence of two 11h-HSD
types could be established. One of the enzymes was a
unidirectional NAD-dependent dehydrogenase with a Km
in the nanomolar range. These characteristics are indicative
for 11h-HSD2 [15]. The other type found in the kidney
Fig. 4. Amino acid sequence of a part of feline 11h-HSD2 in comparison with other species. The underlined amino acids indicate the five regions of the
enzyme. The most prominent regions are region A, the co-factor binding pocket (82–115), and region D, the active site of the enzyme (232–249). The amino
acids underlined separately are mutation sites known to cause AME in humans. The mutations are: deletion of LE, substitution of R187C, R208C, R213C,
R279C, D244N, L250R, L251S, R186C, P227L, R337C and R208H. The circumscribed parts are the conserved parts within the regions of the SCAD
superfamily.
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NADP(H)-dependent enzyme with bidirectional activity.
The affinity for cortisol and cortisone was equal for both
the dehydrogenase and reductase activity. The enzyme
velocity of the dehydrogenase reaction is higher than the
reductase reaction over the entire substrate concentration
range as illustrated in Fig. 1. This indicates predominantdehydrogenase activity of this enzyme in the kidney, en-
abling the feline kidney effectively to convert cortisol into
cortisone over a large substrate concentration range.
The presence of 11h-HSD1 and 11h-HSD2 in the feline
kidney was confirmed by RT-PCR. In the kidney of the rat
[28], mouse [32] and guinea pig [6], activities of both 11h-
HSDs are clearly established. In contrast, in humans only
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ever, in these experiments, only kidney cortex and not
medulla was used. In the medulla of the human kidney,
low mRNA expression and activity of 11h-HSD1 was found
by Whorwood [36]. By selectively cutting out kidney
cortex, this feature is missed in many experiments. We
detected mRNA of 11h-HSD1 and -2 in the feline kidney
cortex and in the medulla. In these experiments, cortex and
medulla were separated visually. Preliminary activity studies
in microsomes of kidney medulla did not show any activity,
whereas in the kidney cortex we could clearly establish
activity of both 11h-HSD1 and 11h-HSD2 (data not
shown). This suggests that both 11h-HSD types are
expressed in the feline kidney, but in particular the cortex
constitutes high enough expression to establish measurable
enzyme activity.
In the feline liver, an NADPH-dependent reductase was
found, with a Km in the micromolar range indicating 11h-
HSD1 [48,49]. Corresponding with the results of the
enzyme kinetic data, RT-PCR confirmed the identity as
11h-HSD1. In most species, 11h-HSD1 has bidirectional
enzyme activity with predominantly reductase activity in
the liver. However, our data could only demonstrate unidi-
rectional reduction. Because of slow reaction velocity
together with the extreme low substrate affinity, no dehy-
drogenase activity was detectable. According to previous
data, we found bidirectional activity of this enzyme in the
kidney [6,28,32]. Hence the enzyme kinetic parameters of
11h-HSD1 in the liver and kidney show remarkable differ-
ences. The Km of 11h-HSD1 was smaller in the kidney
than in the liver (see Tables 1 and 2). Variance in the Km
values of 11h-HSD in different organs has also been
described in guinea pig [6] and rat [50] indicating tissue-
specific features. As the cDNA fragment in the liver was
100% homologous with the 11h-HSD1 fragment found in
the kidney, this strongly suggests that the NADP(H)-de-
pendent form in the kidney is based on the same gene
product as the NADP(H)-dependent form in the liver.
Sequence analysis of the fragments confirmed highly
conserved parts. For each enzyme, the active site and the
cofactor binding pocket are considered to be the best
conserved regions [20]. Comparison of the cofactor binding
pocket of feline 11h-HSD2 with that of other species
showed the highest homology with humans. Only one
amino acid (alanine 104) was different from the human
enzyme (serine 104), whereas in the other species alanine or
threonine was found at this site. Besides this specific amino
acid locus, all other species differ in two to five amino acids
from the binding pocket of human 11h-HSD2, indicating
the cat to be the most closely related species to man.
A very important amino acid near the cofactor binding
pocket in humans is glutamate115 because deletion of this
locus in humans is associated with signs of Apparent
Mineralocorticoid Excess Syndrome (AMES) and hyperten-
sion [51]. At this position glutamate is also found in the cat,
while in the other species aspartate115 is found. Otherfrequent mutation sites described causing AMES in humans
are substitution of R187C, R208C, R213C, R279C, D244N,
L250R, L251S, R186C, P227L, R337C and R208H
[25,51,52]. Another important finding is that cats share with
humans the non-mutated amino acids at all these sites. Thus,
for the diagnosis of AMES and related hypertension, all
these amino acids are of pivotal interest.
At the active site of 11h-HSD2 considerable species
differences exist at position 239 (valine in man, methionine
in cats, leucine in cows, isoleucine in guinea pigs, mice and
rats). This is remarkable because this locus is considered to
be highly conserved in the SCAD superfamily, thus suggest-
ing this amino acid to be the same within one enzyme [20].
Besides this difference, the cat has one other distinct amino
acid (serine 234), but this locus is not within the highly
conserved part of the SCAD superfamily. As at the cofactor
binding pocket, the guinea pig has again the highest diversity
at the active site. Besides the cofactor binding pocket (region
A) and the active site (region D), there are tree other regions
(B, C and E) highly conserved in the SCAD superfamily.
Their physiological function, however, remains to be eluci-
dated. The cat showed 100% homology with humans in these
three regions. Region B is identical in the species described,
in region C the guinea pigs and cows have the exceptional
amino acids in highly conserved parts, and region E showed
differences with humans in all described species except cats.
In the other enzyme, 11h-HSD1, the cofactor binding
pocket of the cat exhibits a 100% homology to humans,
although we were unable to determine the first three amino
acids. At the active site, the cat showed the highest homol-
ogy with man. The other species differ in one ore more
amino acids from the cats and humans [5,29,32,53,54]. At
the active site of 11h-HSD1, cats and cows have methionine
at position 199, while in man and rats this is lysine, in mice
and sheep this is threonine, and in guinea pig this is serine,
indicating a number of possible variations at this site. The
two absolute conserved consensus sites for N-glycosylation
are present in the cat, and most other species, but not in the
guinea pig and sheep where one of these two sites is absent
[5,52].
In conclusion, in the kidney of the cat, the predominant
activity of 11h-HSD is the conversion of cortisol into
cortisone, emphasizing the high capacity of the kidney
for inactivation of cortisol. Two types of 11h-HSD are
commonly found in the kidney: 11h-HSD1 and 11h-HSD2.
With regard to the pathogenesis of hypertension, 11h-
HSD2 is the most important type. Feline 11h-HSD2 has
similar enzyme kinetic parameters as human 11h-HSD2
and the amino acid sequence of the most important parts of
this enzyme shares approximately 90% homology with
human 11h-HSD2. Thus, out of all other species investi-
gated as yet, the 11h-HSD enzymes in the cat resemble
most closely the human form. By performing enzyme
kinetic studies together with sequencing of the most im-
portant regions (and possible mutation sites) of the
enzymes, we created the tools to investigate the presence
L. Schipper et al. / Biochimica et Biophysica Acta 1688 (2004) 68–7776of symptoms of AMES in cats with hypertension. This is of
importance not only for feline patients, but it also implies
that the cat may serve as a model species for studies
directed to the pathogenesis and treatment of AMES and
hypertension in humans.Acknowledgements
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